🇺🇸 FDA
Pipeline program

131I-apamistmab

AAAV1172

Phase 1 small_molecule active

Quick answer

131I-apamistmab for Sickling Disorder Due to Hemoglobin S is a Phase 1 program (small_molecule) at Actinium Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Actinium Pharmaceuticals
Indication
Sickling Disorder Due to Hemoglobin S
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials